Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents

被引：8

作者：

Klein, Nicola P. ^{[1
]}

Demarco, Maria ^{[2
]}

Fleming-Dutra, Katherine E. ^{[3
]}

Stockwell, Melissa S. ^{[4
,5
,6
]}

Kharbanda, Anupam B. ^{[7
]}

Gaglani, Manjusha ^{[8
,9
]}

Rao, Suchitra ^{[10
]}

Lewis, Ned ^{[1
]}

Irving, Stephanie A. ^{[11
]}

Hartmann, Emily ^{[12
]}

Natarajan, Karthik ^{[6
,13
]}

Dalton, Alexandra F. ^{[3
]}

Zerbo, Ousseny ^{[1
]}

DeSilva, Malini B. ^{[14
]}

Konatham, Deepika ^{[8
]}

Stenehjem, Edward ^{[15
]}

Rowley, Elizabeth A. K. ^{[2
]}

Ong, Toan C. ^{[10
]}

Grannis, Shaun J. ^{[16
,17
]}

Sloan-Aagard, Chantel ^{[12
,18
]}

Han, Jungmi ^{[12
]}

Verani, Jennifer R.

Raiyani, Chandni ^{[8
]}

Dascomb, Kristin ^{[15
]}

Reese, Sarah E. ^{[2
]}

Barron, Michelle A. ^{[10
]}

Fadel, William F. ^{[19
]}

Naleway, Allison L. ^{[11
]}

Nanez, Juan ^{[12
]}

Dickerson, Monica ^{[3
]}

Goddard, Kristin ^{[1
]}

Murthy, Kempapura ^{[8
]}

Grisel, Nancy ^{[15
]}

Weber, Zacharay A. ^{[2
]}

Dixon, Brian E. ^{[16
,19
]}

Patel, Palak ^{[3
]}

Fireman, Bruce ^{[1
]}

Arndorfer, Julie ^{[15
]}

Valvi, Nimish R. ^{[16
]}

Griggs, Eric P. ^{[3
]}

Hallowell, Carly ^{[2
]}

Embi, Peter J. ^{[16
,20
]}

Ball, Sarah W. ^{[2
]}

Thompson, Mark G. ^{[3
]}

Tenforde, Mark W. ^{[3
]}

Link-Gelles, Ruth ^{[3
]}

机构：

[1] Kaiser Permanente, Kaiser Permanente Vaccine Study Ctr, Northern Calif Div Res, Oakland, CA USA

[2] Westat Corp, Rockville, MD USA

[3] Ctr Dis Control & Prevent, COVID 19 Response Team, Atlanta, GA USA

[4] Columbia Univ, Dept Pediat, Div Child & Adolescent Hlth, Vagelos Coll Phys & Surg, New York, NY USA

[5] Columbia Univ, Dept Populat & Family Hlth, Mailman Sch Publ Hlth, New York, NY USA

[6] NewYork Presbyterian Hosp, New York, NY USA

[7] Childrens Minnesota, Minneapolis, MN USA

[8] Baylor Scott & White Hlth, Sect Pediat Infect Dis, Dept Pediat, Temple, TX USA

[9] Texas A&M Univ, Dept Med Educ, Coll Med, Temple, TX USA

[10] Univ Colorado Anschutz Med Campus, Dept Pediat, Aurora, CO USA

[11] Kaiser Permanente Ctr Hlth Res, Portland, OR USA

[12] Paso del Norte Hlth Informat Exchange PHIX, El Paso, TX USA

[13] Columbia Univ, Dept Biomed Informat, Irving Med Ctr, New York, NY USA

[14] HealthPartners Inst, Minneapolis, MN USA

[15] Intermt Healthcare, Div Infect Dis & Clin Epidemiol, Salt Lake City, UT USA

[16] Regenstrief Inst Hlth Care, Ctr Biomed Informat, Indianapolis, IN USA

[17] Indiana Univ, Sch Med, Indianapolis, IN USA

[18] Brigham Young Univ, Dept Publ Hlth, Provo, UT USA

[19] Indiana Univ, Fairbanks Sch Publ Hlth, Indianapolis, IN USA

[20] Vanderbilt Univ, Med Ctr, Nashville, TN USA

来源：

PEDIATRICS | 2023年 / 151卷 / 05期

关键词：

COVID-19-ASSOCIATED EMERGENCY-DEPARTMENT; URGENT CARE ENCOUNTERS; VISION NETWORK; UNITED-STATES; HOSPITALIZATIONS; INFECTION;

D O I：

10.1542/peds.2022-060894

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

OBJECTIVESWe assessed BNT162b2 vaccine effectiveness (VE) against mild to moderate and severe coronavirus disease 2019 (COVID-19) in children and adolescents through the Omicron BA.4/BA.5 period. METHODSUsing VISION Network records from April 2021 to September 2022, we conducted a test-negative, case-control study assessing VE against COVID-19-associated emergency department/urgent care (ED/UC) encounters and hospitalizations using logistic regression, conditioned on month and site, adjusted for covariates. RESULTSWe compared 9800 ED/UC cases with 70 232 controls, and 305 hospitalized cases with 2612 controls. During Delta, 2-dose VE against ED/UC encounters at 12 to 15 years was initially 93% (95% confidence interval 89 to 95), waning to 77% (69% to 84%) after & GE;150 days. At ages 16 to 17, VE was initially 93% (86% to 97%), waning to 72% (63% to 79%) after & GE;150 days. During Omicron, VE at ages 12 to 15 was initially 64% (44% to 77%), waning to 13% (3% to 23%) after & GE;150 days; at ages 16 to 17 VE was 31% (10% to 47%) during days 60 to 149, waning to 7% (-8 to 20%) after 150 days. A monovalent booster increased VE to 54% (40% to 65%) at ages 12 to 15 and 46% (30% to 58%) at ages 16 to 17. At ages 5 to 11, 2-dose VE was 49% (33% to 61%) initially and 41% (29% to 51%) after 150 days. During Delta, VE against hospitalizations at ages 12 to 17 was high (>97%), and at ages 16 to 17 remained 98% (73% to 100%) beyond 150 days; during Omicron, hospitalizations were too infrequent to precisely estimate VE. CONCLUSIONSBNT162b2 protected children and adolescents against mild to moderate and severe COVID-19. VE was lower during Omicron predominance including BA.4/BA.5, waned after dose 2 but increased after a monovalent booster. Children and adolescents should receive all recommended COVID-19 vaccinations.

引用

页数：15

共 41 条

[1] Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis
Bhuiyan, Mejbah Uddin
Stiboy, Eunice
Hassan, Md Zakiul
Chan, Mei
Islam, Md Saiful
Haider, Najmul
Jaffe, Adam
Homaira, Nusrat
[J]. VACCINE, 2021, 39 (04) : 667 - 677
[2] Effect of Vaccination on Preventing Influenza-Associated Hospitalizations Among Children During a Severe Season Associated With B/Victoria Viruses, 2019-2020
Campbell, Angela P.
Ogokeh, Constance
Weinberg, Geoffrey A.
Boom, Julie A.
Englund, Janet A.
Williams, John, V
Halasa, Natasha B.
Selvarangan, Rangaraj
Staat, Mary A.
Klein, Eileen J.
McNeal, Monica
Michaels, Marian G.
Sahni, Leila C.
Stewart, Laura S.
Szilagyi, Peter G.
Harrison, Christopher J.
Lively, Joana Y.
Rha, Brian
Patel, Manish
[J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (04) : E947 - E954
[3] Centers for Disease Control and Prevention, CLIN CONS US COVID 1
[4] Centers for Disease Control and Prevention, CDC EXP BOOST SHOT E
[5] Centers for Disease Control and Prevention, HLTH AL NETW INCR RE
[6] Centers for Disease Control and Prevention, CDC STRENGTH REC EXP
[7] Centers for Disease Control and Prevention, CDC EXP COVID 19 BOO
[8] Clarke KEN, 2022, MMWR-MORBID MORTAL W, V71, P606, DOI 10.15585/mmwr.mm7117e3
[9] The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020
Dooling, Kathleen
Marin, Mona
Wallace, Megan
McClung, Nancy
Chamberland, Mary
Lee, Grace M.
Talbot, H. Keipp
Romero, Jose R.
Bell, Beth P.
Oliver, Sara E.
[J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2021, 69 (51-52): : 1657 - 1660
[10] Feldstein LR., 2020, NEW ENGL J MED, V383, P334

← 1 2 3 4 5 →